Grail reports first data from CCGA study

Grail Inc. (Menlo Park, Calif.) reported initial data from a lung cancer substudy of its observational Circulating Cell-Free Genome Atlas (CCGA) study, which aims to create a detailed atlas of cancer genetics. Data were presented at the American Society of Clinical Oncology meeting

Read the full 431 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE